Trial reportDrug design, development and therapy2026
Effect of a Subanesthetic Dose of Esketamine on Postoperative Sleep Disturbance After Oocyte Retrieval Under Intravenous Anesthesia: A Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Postoperative sleep disturbance (PSD) is a common complication after oocyte retrieval under intravenous anesthesia. This study aimed to evaluate whether a subanesthetic dose of esketamine reduces the incidence of PSD. Patients and Methods: This randomized, double-blind, placebo-controlled trial included 196 women undergoing oocyte retrieval under intravenous anesthesia. Participants were randomly assigned to the esketamine or control group. During anesthesia induction, the esketamine group received an intravenous bolus of esketamine 0.2 mg/kg, whereas the control group received an equivalent volume of normal saline. The primary analysis was conducted according to the intention-to-treat principle, with missing outcome data handled using multiple imputation; 189 participants (95 in the control group and 94 in the esketamine group) were included in the per-protocol sensitivity analysis. The primary outcome was the incidence of PSD on postoperative day (POD) 3, defined using a composite criterion of an Athens Insomnia Scale (AIS) score ≥6 or a numerical rating scale (NRS) score ≥6. Secondary outcomes included the incidence of PSD on POD 1, postoperative pain scores, postoperative anxiety and depression scores, and patient satisfaction with the anesthetic technique. Results: In the intention-to-treat analysis with multiple imputation, the estimated incidence of PSD on POD 3 was lower in the esketamine group than in the control group (13.06% vs 24.90%; risk difference, -11.84 percentage points [95% CI, -22.98 to -0.69]; relative risk [RR], 0.52 [95% CI, 0.28-0.99]; Conclusion: A single subanesthetic dose of esketamine was associated with a lower incidence of short-term PSD on POD 3 in women undergoing oocyte retrieval under intravenous anesthesia. Larger multicenter studies are warranted to confirm these findings. Trial Registration: China Clinical Trial Registry Identifier: ChiCTR2500105998.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.